(NASDAQ: FTRE) Fortrea Holdings's forecast annual revenue growth rate of 0.16% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 108.49%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 26.28%.
Fortrea Holdings's revenue in 2025 is $2,733,500,000.On average, 14 Wall Street analysts forecast FTRE's revenue for 2025 to be $243,810,000,000, with the lowest FTRE revenue forecast at $231,480,000,000, and the highest FTRE revenue forecast at $254,520,000,000. On average, 14 Wall Street analysts forecast FTRE's revenue for 2026 to be $241,740,000,000, with the lowest FTRE revenue forecast at $222,390,000,000, and the highest FTRE revenue forecast at $255,150,000,000.
In 2027, FTRE is forecast to generate $248,940,000,000 in revenue, with the lowest revenue forecast at $227,610,000,000 and the highest revenue forecast at $265,410,000,000.